Cargando…
Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease
OBJECTIVE: History of cardiovascular diseases (CVDs) may influence the prognosis of patients hospitalised for COVID-19. We investigated whether patients with previous CVD have increased risk of death and major adverse cardiovascular event (MACE) when hospitalised for COVID-19. METHODS: We included 8...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039226/ https://www.ncbi.nlm.nih.gov/pubmed/33833064 http://dx.doi.org/10.1136/openhrt-2020-001526 |
_version_ | 1783677543989116928 |
---|---|
author | Tessitore, Elena Carballo, David Poncet, Antoine Perrin, Nils Follonier, Cedric Assouline, Benjamin Carballo, Sebastian Girardin, François Mach, Francois |
author_facet | Tessitore, Elena Carballo, David Poncet, Antoine Perrin, Nils Follonier, Cedric Assouline, Benjamin Carballo, Sebastian Girardin, François Mach, Francois |
author_sort | Tessitore, Elena |
collection | PubMed |
description | OBJECTIVE: History of cardiovascular diseases (CVDs) may influence the prognosis of patients hospitalised for COVID-19. We investigated whether patients with previous CVD have increased risk of death and major adverse cardiovascular event (MACE) when hospitalised for COVID-19. METHODS: We included 839 patients with COVID-19 hospitalised at the University Hospitals of Geneva. Demographic characteristics, medical history, laboratory values, ECG at admission and medications at admission were collected based on electronic medical records. The primary outcome was a composite of in-hospital mortality or MACE. RESULTS: Median age was 67 years, 453 (54%) were males and 277 (33%) had history of CVD. In total, 152 (18%) died and 687 (82%) were discharged, including 72 (9%) who survived a MACE. Patients with previous CVD were more at risk of composite outcomes 141/277 (51%) compared with those without CVD 83/562 (15%) (OR=6.0 (95% CI 4.3 to 8.4), p<0.001). Multivariate analyses showed that history of CVD remained an independent risk factor of in-hospital death or MACE (OR=2.4; (95% CI 1.6 to 3.5)), as did age (OR for a 10-year increase=2.2 (95% CI 1.9 to 2.6)), male gender (OR=1.6 (95% CI 1.1 to 2.3)), chronic obstructive pulmonary disease (OR=2.1 (95% CI 1.0 to 4.2)) and lung infiltration associated with COVID-19 at CT scan (OR=1.9 (95% CI 1.2 to 3.0)). History of CVD (OR=2.9 (95% CI 1.7 to 5)), age (OR=2.5 (95% CI 2.0 to 3.2)), male gender (OR=1.6 (95% CI 0.98 to 2.6)) and elevated C reactive protein (CRP) levels on admission (OR for a 10 mg/L increase=1.1 (95% CI 1.1 to 1.2)) were independent risk factors for mortality. CONCLUSION: History of CVD is associated with higher in-hospital mortality and MACE in hospitalised patients with COVID-19. Other factors associated with higher in-hospital mortality are older age, male sex and elevated CRP on admission. |
format | Online Article Text |
id | pubmed-8039226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-80392262021-04-13 Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease Tessitore, Elena Carballo, David Poncet, Antoine Perrin, Nils Follonier, Cedric Assouline, Benjamin Carballo, Sebastian Girardin, François Mach, Francois Open Heart Cardiac Risk Factors and Prevention OBJECTIVE: History of cardiovascular diseases (CVDs) may influence the prognosis of patients hospitalised for COVID-19. We investigated whether patients with previous CVD have increased risk of death and major adverse cardiovascular event (MACE) when hospitalised for COVID-19. METHODS: We included 839 patients with COVID-19 hospitalised at the University Hospitals of Geneva. Demographic characteristics, medical history, laboratory values, ECG at admission and medications at admission were collected based on electronic medical records. The primary outcome was a composite of in-hospital mortality or MACE. RESULTS: Median age was 67 years, 453 (54%) were males and 277 (33%) had history of CVD. In total, 152 (18%) died and 687 (82%) were discharged, including 72 (9%) who survived a MACE. Patients with previous CVD were more at risk of composite outcomes 141/277 (51%) compared with those without CVD 83/562 (15%) (OR=6.0 (95% CI 4.3 to 8.4), p<0.001). Multivariate analyses showed that history of CVD remained an independent risk factor of in-hospital death or MACE (OR=2.4; (95% CI 1.6 to 3.5)), as did age (OR for a 10-year increase=2.2 (95% CI 1.9 to 2.6)), male gender (OR=1.6 (95% CI 1.1 to 2.3)), chronic obstructive pulmonary disease (OR=2.1 (95% CI 1.0 to 4.2)) and lung infiltration associated with COVID-19 at CT scan (OR=1.9 (95% CI 1.2 to 3.0)). History of CVD (OR=2.9 (95% CI 1.7 to 5)), age (OR=2.5 (95% CI 2.0 to 3.2)), male gender (OR=1.6 (95% CI 0.98 to 2.6)) and elevated C reactive protein (CRP) levels on admission (OR for a 10 mg/L increase=1.1 (95% CI 1.1 to 1.2)) were independent risk factors for mortality. CONCLUSION: History of CVD is associated with higher in-hospital mortality and MACE in hospitalised patients with COVID-19. Other factors associated with higher in-hospital mortality are older age, male sex and elevated CRP on admission. BMJ Publishing Group 2021-04-08 /pmc/articles/PMC8039226/ /pubmed/33833064 http://dx.doi.org/10.1136/openhrt-2020-001526 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Cardiac Risk Factors and Prevention Tessitore, Elena Carballo, David Poncet, Antoine Perrin, Nils Follonier, Cedric Assouline, Benjamin Carballo, Sebastian Girardin, François Mach, Francois Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease |
title | Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease |
title_full | Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease |
title_fullStr | Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease |
title_full_unstemmed | Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease |
title_short | Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease |
title_sort | mortality and high risk of major adverse events in patients with covid-19 and history of cardiovascular disease |
topic | Cardiac Risk Factors and Prevention |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039226/ https://www.ncbi.nlm.nih.gov/pubmed/33833064 http://dx.doi.org/10.1136/openhrt-2020-001526 |
work_keys_str_mv | AT tessitoreelena mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease AT carballodavid mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease AT poncetantoine mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease AT perrinnils mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease AT folloniercedric mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease AT assoulinebenjamin mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease AT carballosebastian mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease AT girardinfrancois mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease AT machfrancois mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease |